David Malek, BioLine RX: Building a robust pipeline of promising therapeutics for better health




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: David Malek, BioLine RX: Building a robust pipeline of promising therapeutics for better health
Released on: February 19, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview filmed at BIO Europe 2013 in Vienna, Paul Larsmon chats to David Malek, Vice President, Business Development at BioLine RX.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview filmed at BIO Europe 2013 in Vienna, Paul Larsmon chats to David Malek, Vice President, Business Development at BioLine RX. BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies. BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
In this interview filmed at BIO Europe 2013 in Vienna, Paul Larsmon chats to David Malek, Vice President, Business Development at BioLine RX. BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies. BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
David Malek
BioLine RX
BioLineRx Ltd.
BioLineRx is a clinical-stage, publicly-traded, (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company's declared aim is to develop products suitable for today's pharmaceutical market satisfying an unmet medical need or exhibiting features and benefits above those of current therapies. BioLineRx's close ties to technology transfer offices, research institutes, academic institutions and biotechnology companies, both in Israel and around the world, enable access to promising compounds at an early stage. The Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance promising drug candidates, supported and assisted by our distinguished panel of scientific advisers. In this manner the project quickly reaches successful fruition- partnerships with pharmaceutical companies for the final stages of clinical development and commercialization. The BioLineRx business model involves three stages- "Bench to Bedside to Partner". The first stage involves a stringent selection process. BioLineRx's expert team is particularly specialized at evaluating potential drug candidates from both scientific and marketing perspectives. Next, BioLineRx performs development through Phase II proof of concept studies. Finally, BioLineRx partners with pharmaceutical companies to complete the clinical development and bring the product to market.